P
PvP Biologics
Developing a highly-effective therapeutic that reduces the burden of living with celiac disease
About PvP Biologics
PvP Biologics is a biotechnology company focused on developing innovative treatments for celiac disease, a condition affecting approximately 2.4 million Americans. The company's core product, KumaMax, is an oral enzyme designed to break down the immuno-reactive parts of gluten in the stomach, thereby preventing the painful symptoms and intestinal damage caused by accidental gluten ingestion. PvP Biologics operates in the healthcare and biotechnology market, primarily serving patients diagnosed with celiac disease who struggle to maintain a strict gluten-free diet. The business model revolves around the development and commercialization of this therapeutic enzyme, with revenue generated through product sales and potential licensing agreements. The technology behind KumaMax was invented at the Institute for Protein Design at the University of Washington and is exclusively licensed by PvP Biologics.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- San Diego, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 58.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning PvP Biologics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2020 | $0 | — | Takeda | ↗ |
| OtherOther financing | Jan 2018 | $0 | — | Sahsen Ventures | — |
Growth signals
Latest recorded traffic for PvP Biologics is 250 monthly website visits, up 4.2% over the last three months. PvP Biologics's team declined 66.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Takeda
Other known investors2 additional known investors
Sahsen Ventures
University of Washington Institute for Protein Design
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about PvP Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PvP Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.